Komori
Other Disclosures4596Kubota Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice of the Launch of the "Kubota Glass" Monthly Subscription Service

For the myopia progression care device "Kubota Glass®," a monthly service premised on 24 months of continuous use was launched on 13 April 2026, in addition to the existing one-time purchase option.

Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
12000
¥ (excluding tax)/month × 24 months (initial fee separate)
Wording
Avoiding a definitive answer
How definitive the wording is.

Announced details

Kubota Glass®Kubota Glass® My Vision Program2 for You Campaign
Applicable field (uses covered by this announcement)

Myopia progression care

Launch date13 April 2026 (actual)
What the company reported numerically
Usage history

Since its launch in 2022, the product has received a certain level of support from ophthalmology specialists, researchers and early-adopter customers.

Location (as indicated in this announcement)

Tokyo company-operated store

Offering price

Initial fee: ¥39,000 (excluding tax, during the campaign period); planned price after the campaign ends: ¥50,000 (excluding tax); monthly fee: ¥12,000 (excluding tax) × 24 months

Impact on Business Performance

The impact on financial results will be examined further. It is currently difficult to provide an outlook for the number of short-term applications.

The company does not address Contract Value.

Announced details
ItemDetails
Names of Products / Services CoveredKubota Glass®, Kubota Glass® My Vision Program, 2 for You Campaign
Offering priceInitial fee: ¥39,000 (excluding tax, during the campaign period); planned price after the campaign ends: ¥50,000 (excluding tax); monthly fee: ¥12,000 (excluding tax) × 24 months
Launch date13 April 2026 (actual)
Applicable areaMyopia progression care
LocationTokyo company-operated store
Usage historySince its launch in 2022, the product has received a certain level of support from ophthalmology specialists, researchers and early-adopter customers.
Impact on Business PerformanceThe impact on financial results will be examined further. It is currently difficult to provide an outlook for the number of short-term applications.
Items this document does not state (11)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To expand access among customers for whom the one-time purchase had been a barrier to making a purchase decision, establish a recurring and highly predictable revenue base, and validate the business model for future global expansion.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Launch of the "Kubota Glass" Monthly Subscription Service | Kubota Pharmaceutical Holdings Co.,Ltd. (4596) timely disclosure | Komori